Dupilumab enables glucocorticoid withdrawal in refractory multisite mucous membrane pemphigoid: a case report. [PDF]
Hu Y, Xu LL, Li KH, Yu CS, Wang SB.
europepmc +1 more source
Multidisciplinary wound care in an elderly patient with extensive bullous pemphigoid: a case report. [PDF]
Chen X, Mohammadnezhad M, Zhou Y, Qin Y.
europepmc +1 more source
Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With Diabetes. [PDF]
Mahajan A +5 more
europepmc +1 more source
Mucous membrane pemphigoid associated with thymoma: A rare cancer-associated immune manifestation. [PDF]
Fakih A, Makarem J, Sabbah N, Harb SB.
europepmc +1 more source
A case of anti-laminin 332-type mucous membrane pemphigoid mimicking linear IgA bullous dermatosis. [PDF]
Du X, Dang J, Zhao J, Shang P.
europepmc +1 more source
KCNQ1 rs163184 Variant Modulates Susceptibility to Classic and DPP-4 Inhibitor-Associated Bullous Pemphigoid. [PDF]
Agiannitopoulos K +8 more
europepmc +1 more source
Personalized Biologic Therapy for Refractory Bullous Pemphigoid: Sequential Omalizumab, Dupilumab, and Rituximab. [PDF]
Yu L +5 more
europepmc +1 more source
Immunofluorescence of Autoimmune Bullous Diseases
Autoimmmune bullous diseases of skin and mucosa are uncommon, disabling, and potentially lethal diseases. For a quick and reliable diagnosis immunofluorescence is essential. This article describes two variants of immunofluorescence. The direct method uses a skin or mucosal biopsy of the patient to detect in vivo bound antibodies.
Gilles F, Diercks +2 more
openaire +3 more sources
Mucosal anomalies in autoimmune bullous diseases [PDF]
Mucosal anomalies are frequently seen in autoimmune bullous diseases, particularly in pemphigus vulgaris and mucous membrane pemphigoid. The blistering, erosions, ulceration or erythema may present anywhere on the oral mucosa, but also on other mucosal sites.
J M, Meijer, A, Vissink
openaire +3 more sources

